Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, noviembre 20
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Avalo Therapeutics Inc
AVTX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$6.75
-0.005
-0.07%
Últ. Act.: Nov 20, 3:15 PM
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Avalo Therapeutics Financials
Avalo Therapeutics (AVTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Avalo Therapeutics Q3 EPS $(0.34) Beats $(0.61) Estimate
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.61) by 44.26 percent. This is a 84.47 percent increase over losses of $(2.19) per share
Benzinga Newsdesk
Nasdaq Down 400 Points; Tesla Shares Fall After Q3 Results
US stocks fell, led by Nasdaq’s 1.54% drop. Tesla slid 2% despite an earnings beat; oil rose, while gold and Asian markets declined.
Avi Kapoor
PRO
Avalo Therapeutics Q2 EPS $(0.83) Misses $(0.58) Estimate
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.58) by 43.1 percent. This is a 56.77 percent increase over losses of $(1.92) per share
Benzinga Newsdesk
PRO
Avalo Therapeutics Q1 EPS $(0.98) Beats $(1.13) Estimate
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.13) by 13.27 percent. This is a 21.6 percent increase over losses of $(1.25) per share from
Benzinga Newsdesk
Earnings Scheduled For March 23, 2026
Benzinga Insights
PRO
Avalo Therapeutics Q4 EPS $(0.48) Beats $(1.47) Estimate, Sales $59.000K Down From $192.000K YoY
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(1.47) by 67.3 percent. This is a 127.91 percent decrease over earnings of $1.72 per share
Benzinga Newsdesk